General
Preferred name
mavorixafor
Synonyms
X4P-001 ()
AMD-070 hydrochloride ()
Mavorixafor (hydrochloride) ()
AMD-070 (hydrochloride) ()
AMD-070 (trihydrochloride) ()
AMD-11070 (trihydrochloride) ()
AMD-070 ()
Mavorixafor (trihydrochloride) ()
AMD070 ()
AMD11070 ()
X4p001 ()
Amd 070 ()
AMD-11070 ()
X 4P-001 ()
Cxcr4 inhibitor x4p-001 ()
P&D ID
PD048784
CAS
880549-30-4
558441-90-0
558447-26-0
2309699-17-8
Tags
available
drug
Drug indication
Melanoma
Solid tumour/cancer
Merkel cell carcinoma
Renal cell carcinoma
Human immunodeficiency virus infection
Whim syndrome
Drug Status
investigational
approved
Max Phase
3.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION AMD070 is a potent, selective and bioavailable CXCR4 chemokine receptor antagonist . Originally developed for HIV treatment, it has now being repurposed by X4 Pharmaceuticals as X4P-001 for the treatment of WHIM syndrome, a sub-type of a primary immunodeficiency disease caused by CXCR4 mutations. The compound is exemplified in a process patent US7332605 and as compound 89 from a series of 169 analogues in WO2003055876 but neither filing includes activity data.
DESCRIPTION Mavorixafor (AMD070/AMD11070) is a potent, selective and bioavailable CXCR4 chemokine receptor allosteric antagonist . Originally developed for HIV treatment , it was repurposed by X4 Pharmaceuticals as X4P-001 for the treatment of WHIM syndrome, a sub-type of a primary immunodeficiency disease caused by CXCR4 mutations. The compound is exemplified in a process patent US7332605 and as compound 89 from a series of 169 analogues in WO2003055876 but neither filing includes activity data. (GtoPdb)
PHARMACODYNAMICS AMD-070 is a small molecule drug candidate that belongs to a new investigational class of anti-HIV drugs known as entry (fusion) inhibitors. Approximately 76% of HIV-patients with measurable viral load are infected with a strain of virus that is resistant to one or more classes of antiretroviral agents, thus reducing treatment options. Unlike many existing HIV drugs that target the virus after it has infected a healthy cell, AMD-070 blocks the virus from entering a healthy cell, thus preventing the replication process. AMD-070 targets the CXCR4 receptor on HIV and prevents the virus from entering and infecting healthy cells. ; * AMD-070 is specific for the CXCR4 receptor and does not interact with any other chemokine receptors in vitro; * AMD-070 strongly inhibits viral infection by all CXCR4 using virus (including virus using CXCR4 alone and/or virus using CXCR4 and CCR5) in vitro; * AMD-070 is orally bioavailable in animals; * Suitable PK and toxicity profile for oral dosing; * AMD-070 shows additive or synergistic effects in vitro in combination with other known anti-HIV agents; * AMD-070 is active against CXCR4 using HIV strains that are resistant to existing antiretroviral therapies in vitro; * Potent anti-HIV activity against CXCR4-using laboratory strains and clinical isolates;
MOA Chemokine receptors expressed on the surface of immune cells are known to play a critical role in virus infection and transmission. CXCR4, and another chemokine receptor CCR5, are involved in HIV infection.; ; The process of HIV entry begins with binding of the viral envelope glycoprotein to both the CD4 receptor and one of only two chemokine receptors, and ends with fusion of viral and cell membranes. Viral entry provides novel therapeutic targets against HIV. To date, at least 3 sub classes of HIV viral entry/fusion inhibitors have emerged:; ; 1. CD4 binding or attachment - targets initial recognition and binding of the viral glycoprotein gp120 to the cell-surface CD4 antigen.; 2. Chemokine co-receptor binding - targets binding of virus to the CCR5 or CXCR4 co-receptor.; 3. Fusion Inhibition - targets the viral glycoprotein gp41 inhibiting the fusion of virus with the cell.; ; ; Different strains of HIV prefer one receptor or the other, or may use either receptor to infect cells.; ; * 35% of strains use both CXCR4 and CCR5; * 5% of strains are pure CXCR4 using; * 60% of strains are pure CCR5 using; * An infected individual may harbor different levels of both CXCR4 and CCR5 using virus; * CXCR4 using virus independently predicts CD4 decline and HIV clinical progression and is associated with earlier mortality; ;
Cell lines
0
Organisms
1
Compound Sets
18
AdooQ Bioactive Compound Library
A14997
Cayman Chemical Bioactives
28439
ChEMBL Drugs
CHEMBL518924
Concise Guide to Pharmacology 2017/18
8580
Concise Guide to Pharmacology 2019/20
8580
Concise Guide to Pharmacology 2021/22
8580
Concise Guide to Pharmacology 2023/24
8580
Drug Repurposing Hub
DrugBank
DB05501
DrugMAP
DMVOY6B
EU-OPENSCREEN Bioactive Compound Library
EOS101822
Guide to Pharmacology
8580
Mcule NIBR MoA Box Subset
MCULE-2659873916
MedChem Express Bioactive Compound Library
HY-50101A
Novartis Chemogenetic Library (NIBR MoA Box)
ReFrame library
Selleckchem Bioactive Compound Library
mavorixafor
TargetMol Bioactive Compound Library
T22565
External IDs
44
Properties
(calculated by RDKit )
Molecular Weight
349.23
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
7
Ring Count
4
Aromatic Ring Count
3
cLogP
3.58
TPSA
70.83
Fraction CSP3
0.43
Chiral centers
1.0
Largest ring
6.0
QED
0.64
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
HIV
CXCR4
CCR5, CXCR4
CXCR
Pathway
GPCR/G protein
Immunology/Inflammation
Anti-infection
Autophagy
Member status
member
MOA
CXCR4 antagonist, HIV attachment inhibitor
CC chemokine receptor antagonist
Source data